Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation

Verena Leidgens¹, Judith Proske¹,*, Lisa Rauer¹,*, Sylvia Moeckel¹, Kathrin Renner², Ulrich Bogdahn¹, Markus J. Riemenschneider³, Martin Proescholdt⁴, Arabel Vollmann-Zwerenz¹, Peter Hau¹, Corinna Seliger¹

¹Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg, Regensburg, Germany
²Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany
³Department of Neuropathology, Regensburg University Hospital, Regensburg, Germany
⁴Department of Neurosurgery, University Hospital Regensburg, Regensburg, Germany

*These authors have contributed equally to this work

Correspondence to: Corinna Seliger, email: corinna.seliger@klinik.uni-regensburg.de

Keywords: glioma, BTIC, STAT3, Stattic, metformin

Received: August 20, 2016       Accepted: November 21, 2016       Published: December 24, 2016

ABSTRACT

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor and associated with a devastating prognosis. Signal transducer and activator of transcription number 3 (STAT3) is an important pathogenic factor in GBM and can be specifically inhibited with Stattic. Metformin inhibits GBM cell proliferation and migration. Evidence from other tumor models suggests that metformin inhibits STAT3, but there is no specific data on brain tumor initiating cells (BTICs).

We explored proliferation and migration of 7 BTICs and their differentiated counterparts (TCs) after treatment with Stattic, metformin or the combination thereof. Invasion was measured in situ on organotypic brain slice cultures. Protein expression of phosphorylated and total STAT3, as well as AMPK and mTOR signaling were explored using Western blot. To determine functional relevance of STAT3 inhibition by Stattic and metformin, we performed a stable knock-in of STAT3 in selected BTICs.

Inhibition of STAT3 with Stattic reduced proliferation in all BTICs, but only in 4 out of 7 TCs. Migration and invasion were equally inhibited in BTICs and TCs. Treatment with metformin reduced STAT3-phosphorylation in all investigated BTICs and TCs. Combined treatment with Stattic and metformin led to significant additive effects on BTIC proliferation, but not migration or invasion. No additive effects on TCs could be detected. Stable STAT3 knock-in partly attenuated the effects of Stattic and metformin on BTICs.

In conclusion, metformin was found to inhibit STAT3-phosphorylation in BTICs and TCs. Combined specific and unspecific inhibition of STAT3 might represent a promising new strategy in the treatment of glioblastoma.

INTRODUCTION

High-grade gliomas, especially glioblastomas (GBM), are highly complex and heterogeneous primary brain tumors, accounting for about 30% of all tumors of the central nervous system [1]. Glioblastomas are nearly uniformly fatal with median overall survival ranging between 14.6 and 26.3 months in patients treated within clinical studies [2, 3]. Brain tumor initiating cells (BTICs) represent cancer stem-like progenitor cells, which are not only implicated in tumor initiation, but also in recurrence and progression [4–6]. BTICs are characterized by self-renewal, clonogenicity, pluripotency, and closely resemble the histopathological phenotype of parental tumors after implantation of these cells into athymic mice [6]. Persistent activation of STAT3 (signal transducer and activator of transcription number 3) has been detected in many cancers [7], including gliomas, and is correlated...
with poor survival [8]. This was confirmed by correlation of strong expression of STAT3 phosphorylated at Y705 in GBM specimens with a more aggressive phenotype and shorter overall survival [9]. A series of elegant studies has demonstrated an important role of STAT3 in gliomas in vivo and in vitro. Evidence has emerged, that STAT3 is required by BTICs to maintain their stem-like characteristics [10]. RNA interference of STAT3 sufficiently led to growth arrest, inhibited neurosphere-formation and could induce apoptosis in BTICs [11]. Hence, STAT3 inhibitors have become a major interest in neuro-oncology. The STAT inhibitor Stattic [12] was shown to selectively inhibit STAT3 [13]. However, it is still unclear whether Stattic binds directly to the phosphorylation site at Y705 or if it acts by altering the conformation of the SH2 domain, because it binds to Cys687 on the opposite side of the phosphopeptide binding face [13].

Metformin (1,1-dimethylbiguanide hydrochloride) is a biguanide drug mainly prescribed in the treatment of type 2 diabetes [14]. Metformin has also antineoplastic effects and may reduce the risk of certain cancer types in diabetic patients [15, 16]. Several in vitro studies revealed anti-proliferative effects of metformin on cancer stem cells [17], glioma initiating cells [18, 19], and human GBM lines [20]. Known mechanisms of action of metformin are the inhibition of complex I of the respiratory chain [21], resulting in activation of AMPK (adenosine monophosphate-activated protein kinase) and the inhibition of mTOR (mammalian Target Of Rapamycin) [22]. Interestingly, metformin has been shown to reduce STAT3-phosphorylation in a study investigating triple-negative breast cancer [23]. Similar effects could also be shown in two established GBM lines [24].

The primary aim of our study was to better characterize the effects of STAT3 inhibition on primary BTICs and their differentiated counterparts. In addition to specific STAT3 inhibition with Stattic, we investigated whether metformin inhibits STAT3-phosphorylation in BTICs and whether additive effects can be achieved by combining Stattic with the approved and clinically well-tolerated anti-diabetic drug metformin.

RESULTS

Characteristics of brain tumor initiating cells

All primary BTICs used here were derived from patients, who had undergone resection of WHO grade IV gliomas at the Neurosurgery Department of the University Hospital Regensburg [19, 25]. Primary cell lines were established and used in low (typically below passage 8) passage numbers to assure maximum resemblance to original tumor cells. O6-methylguanine-DNA methyltransferase (MGMT) methylation status varied in-between the lines, while all lines were isocitrate dehydrogenase 1-(IDH1) wild type in culture. BTIC-13 lost its IDH1 R132H mutation under culture conditions (Table 1). Cells were kept as BTICs under serum free conditions, and after withdrawal of growth factors and addition of 10% serum to the cell culture medium as differentiated tumor cells (TCs).

Stattic treatment reduces proliferation and migration of BTICs and TCs

First, we investigated the effects of different doses of Stattic on proliferation (Figure 1) and migration (Figure 2) of BTICs and TCs. Proliferation was assessed after 48 and 96 h to ensure sufficient proliferation while simultaneously avoiding cell death due to high confluence. Migration was analyzed at 16, 24, 40 and 48 h, to provide also early time points (16, 24 h), when migration is not confounded by proliferation. The reduction of proliferation and migration caused by Stattic was dose-dependent and cell line-dependent. High doses of Stattic (10 – 15 μM) inhibited proliferation in all BTIC lines and in 4 out of 7 respective TC lines significantly and in two other lines noticeably (Figure 1 and Supplementary Figure 1). Protein expression of pSTAT3 at Y705 was dose-dependently reduced after Stattic treatment (24 h), while total STAT3 was not affected, as assessed by Western blot (Figure 1F). When investigating migration at early time points (24 h), high doses of Stattic restricted migration in 6 out of 7 BTIC lines and in all TC lines (Figure 2 and Supplementary Figure 2). When comparing sensitivity of BTICs and TCs, BTICs were significantly more sensitive to Stattic than TCs regarding proliferation (Figure 1E), but also differed according to their basal proliferative capacity, which is observable when comparing the DMSO controls. Migration did not differ between BTICs and TCs (Figure 2E).

STAT3-overexpression enhances proliferation and migration

We assessed effects of STAT3-overexpression on proliferation, migration, and Stattic sensitivity in exemplary cell lines (BTIC-8 and -13). We chose BTIC-8 and -13 due to their good response to Stattic as wild type cells, which unmask a reduction of inhibitory effects more easily than in cells that already respond less in the wild type state. Markedly increased levels of STAT3 were confirmed via qRT-PCR (Figure 3A, 3B) and Western blot (Figure 3C) upon transfection with the STAT3 construct. Stattic treatment led to weaker effects on STAT3-phosphorylation in STAT3-overexpressing cells (Supplementary Figure 3). Upon STAT3-overexpression, BTIC-8 revealed significantly increased proliferation after 96 h (Figure 3D). Sensitivity to Stattic appeared slightly weaker in both lines for some Stattic concentrations, but the results did not reach statistical significance. Migration was enhanced due to increased STAT3 expression (Figure 3F, 3G), but sensitivity to Stattic did not differ
Table 1: Patient characteristics

<table>
<thead>
<tr>
<th>Histology</th>
<th>WHO Grade</th>
<th>MGMT meth.</th>
<th>IDH1</th>
<th>Age</th>
<th>Gender</th>
<th>OS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTIC-7</td>
<td>Primary GBM</td>
<td>IV</td>
<td>–</td>
<td>52</td>
<td>f</td>
<td>16.3</td>
</tr>
<tr>
<td>BTIC-8</td>
<td>Primary GBM</td>
<td>IV</td>
<td>–</td>
<td>52</td>
<td>f</td>
<td>4.0</td>
</tr>
<tr>
<td>BTIC-10</td>
<td>Primary GBM</td>
<td>IV</td>
<td>+</td>
<td>46</td>
<td>m</td>
<td>18.8</td>
</tr>
<tr>
<td>BTIC-11</td>
<td>Primary GBM</td>
<td>IV</td>
<td>+</td>
<td>55</td>
<td>m</td>
<td>17.5</td>
</tr>
<tr>
<td>BTIC-12</td>
<td>Gliosarcoma</td>
<td>IV</td>
<td>+</td>
<td>69</td>
<td>m</td>
<td>16.5</td>
</tr>
<tr>
<td>BTIC-13</td>
<td>Secondary GBM</td>
<td>IV</td>
<td>R132H</td>
<td>42</td>
<td>m</td>
<td>8.5</td>
</tr>
<tr>
<td>BTIC-18</td>
<td>Primary GBM</td>
<td>IV</td>
<td>–</td>
<td>49</td>
<td>m</td>
<td>20.5</td>
</tr>
</tbody>
</table>

Seven different BTICs and their differentiated counterparts were used for *in vitro* assays. All BTICs were derived from WHO grade IV gliomas. While MGMT methylation status differed between lines, IDH mutation was negative for all cells in culture (R132H mutation in BTIC-13 was lost under culture conditions).

Figure 1: Proliferation is reduced upon Stattic treatment. Exemplary proliferation of BTIC-8 A. and -13 B. and respective TC-8 C. and -13 D. upon Stattic treatment at indicated concentrations (2.5, 5, 10, 15 μM). E. Proliferation of BTICs (summarized for BTIC-7, -8, -10, -11, 12, -13, -18) was affected significantly more than that of the respective TCs (summarized for TC-7, -8, -10, -11, 12, -13, -18). F. Stattic treatment (24 h) reduced phosphorylation of STAT3 as exemplarily shown in Western blot analysis of BTIC-11. Corresponding GAPDH controls are indicated by use or not use of the asterisk.
substantially between wild type and knock-in (Figure 3F, 3G).

**BTIC motility is affected by Stattic in an in situ 3D model**

Spheroids of lentivirally transduced and fluorescence tagged BTIC-8, BTIC-10, BTIC-12 and BTIC-13 were implanted on OBSCs (organotypic brain slice cultures). Migration areas were analyzed over 14 days in vitro (=div) and normalized to 0-h spheroid expansion areas. Treatment of OBSCs with Stattic (15 μM) led to significantly reduced invasion in all investigated BTICs and TCs (Figure 4A-4D). In BTIC-8 and TC-8 Stattic treatment led to slightly reduced invasion between day 0 and day 7, but the cells were hardly detected anymore at day 14, indicating cytotoxicity. Exemplary pictures of invading BTIC-13 are shown in Figure 4E. BTICs tended to migrate farther than TCs, but both groups had similar migratory potential after treatment with 15 μM Stattic.

**Metformin inhibits STAT3-phosphorylation**

Based on the results above and published effects of metformin on BTICs [18, 19], we next investigated STAT3-phosphorylation at Y705 and S727 after...
treatment with increasing doses of metformin (Figure 5).
Following a 48 h treatment, metformin inhibited STAT3-phosphorylation in all investigated BTICs and TCs (Figure 5 and Supplementary Figure 4). Signaling pathways known to be influenced by metformin (activation of AMPK and inhibition of mTOR) are shown as positive control in BTIC-11. STAT3 knock-in opposed (low dose) or weakened (high-dose) the effects of metformin treatment, as shown exemplarily in BTIC-8 (S4D).

**DISCUSSION**

For the first time, we were able to demonstrate that metformin in combination with specific STAT3 inhibition by Stattic additively reduced proliferation in a multitude of primary human BTICs. Furthermore, we observed that metformin inhibited phosphorylation of STAT3 in all BTICs and TCs. On the contrary, the combination of Stattic and metformin affected migration of BTICs and TCs to a lower extent in all primary lines. Stable knock-in of STAT3 led to a slight attenuation of the observed effects, while proliferation and partly migration was enhanced.

Many studies have been performed to identify and understand aberrant regulation of STAT3 and its impact on proliferation, migration, and invasion. Among those, Bromberg et al. [26] reported that dominant-negative STAT3 abrogated oncogenic transformation, whereas constitutively activated STAT3C [27] mutants induced it. Furthermore, STAT3 was shown to be essential in human glioma cells to maintain their tumor initiating capacity and the ability to invade the normal brain [10]. These findings indicated STAT3 as a promising target for anticancer therapy.

Stattic was used in concentrations ranging from 2.5 to 15 μM to reveal minimal dosages required for proliferation and migration restriction in vitro. Although in vitro studies reported cell cytotoxicity even with low Stattic concentrations, in vivo animal studies revealed no

**Figure 3: Effects of STAT3-overexpression in BTICs.** A, B. STAT3-overexpression was confirmed by qRT-PCR and Western blot C. Corresponding GAPDH controls are indicated by use or not use of the asterisk. D, E. Proliferation of wild type and STAT3-overexpressing BTIC-8 and BTIC-13 upon Stattic treatment. F, G. Migration of wild type and STAT3-overexpressing BTIC-8 and BTIC-13 upon Stattic treatment.
Figure 4: Effects of STAT3 inhibition in BTICs and TCs on OBSCs. A-D. Spheroid expansion area of BTIC-8, -10, -12 and -13 and respective TCs on OBSCs with or without treatment with 15 μM Stattic every other day. Exemplary pictures of BTIC-13 are shown in (E).

Figure 5: Metformin reduces STAT3-phosphorylation. Western blot analyses of BTIC-11 A., -8 B. and -13 C. revealed reduced levels of phosphorylated STAT3 at Y705 and S727 after 48 h of metformin treatment. Activated AMPK and reduced mTOR signaling are displayed as positive controls (A). Similar effects were seen in respective TC-8 D. and -13 E. Corresponding GAPDH controls are indicated by the same number of asterisks/pounds signs.
signs of severe side effects using Stattic concentrations distinctly exceeding those used in vitro. In line with this, Lin et al. [28] demonstrated high cell cytotoxicity rates in GBM cell lines in vitro even with low Stattic concentrations (0.73 μM U87 and 0.84 μM U251), whereas others administered 3.75 mg kg⁻¹ Stattic [29] or 10 mg kg⁻¹ subcutaneously [30] without side effects in their animal models. Missing side effects are likely due to the fact that STAT3 may not be essential for viability of normal cells in adult mammalians [7].

According to the cancer stem cell model, tumor recurrence after initial treatment results from remaining, therapy-resistant cancer stem cells (reviewed in [31]). In our study, substantially lower Stattic concentrations were required to restrict proliferation of BTICs than of TCs, indicating a more important role of STAT3 in BTIC proliferation than in TCs or a higher pharmacological susceptibility. Although therapy-resistance of cancer stem cells is widely assumed, it lacks conclusive experimental evidence [31]. Consequently, it may not be excluded that inhibition of a central transcription factor as STAT3 has profound consequences for those tumor cells, namely BTICs, that contain self-renewal and multilineage differentiation capacity in contrast to more differentiated tumor cells, especially since loss of STAT3 was shown to be lethal in embryonic stem cells [32]. STAT3 was shown to be critically involved in cell survival and cell cycle progression, particularly via induction of c-myc and several cyclins [33], as well as to contribute essentially to maintain the ability to invade the normal brain [10]. It is likely that BTICs depend more on STAT3 for their cell cycle progression, while STAT3 contributes equally to migration and proliferation in differentiated tumor cells. In addition, our BTICs were cultured in Epidermal Growth Factor Receptor (EGFR) enriched culture medium. EGFR is commonly upregulated in glioblastomas [34], and high expression of EGFR leads to Akt-activation through the phosphatidylinositol 3-kinase pathway [35] and increased pSTAT3 expression [36]. It therefore seems plausible, that BTICs respond better to STAT3 inhibition due to enhanced expression of the therapeutic target, which will likely also be the case under physiological conditions in the patient.

Stable knock-in of STAT3 slightly attenuated the effects of Stattic on the functional level and on protein expression, which is most likely explained by the fact, that the overexpressing form is constitutively active. The difference of effects of wildtype and STAT3-

Figure 6: Effects of the combination of Stattic and metformin on proliferation of BTICs and TCs. A, B. Proliferation of BTIC-8 and -13 and C, D. TC-8 and -13 upon treatment with 1 mM metformin without or with the addition of 2.5, 5 and 10 μM Stattic, respectively. E. Proliferation of BTICs (summarized for BTIC-7, -8, -10, -11, 12, -13, -18) was affected significantly more by the combination of metformin and Stattic than of respective TCs (summarized for TC-7, -8, -10, -11, 12, -13, -18). Asterisks indicate significant differences as compared to the corresponding DMSO-control, the pound signs indicate significance as compared to 1 mM metformin.
overexpressing cells however remained only moderate, which might either be explained by insufficient functioning of the constitutively active form of STAT3 or by Static not being fully specific for the inhibition of the Tyr705 phosphorylation site.

In line with our observations for Static, we observed a similar decrease in STAT3-phosphorylation under metformin treatment. Also, combined treatment with metformin and Static led to additive effects and STAT3 knock-in partly abrogated the effects of metformin.

Metformin is an approved and well-tolerated drug for the treatment of type 2 diabetes [37]. In addition, metformin was proven to inhibit proliferation [17, 19, 22, 38, 39] and invasion [40], to induce apoptosis [22, 38, 39] and autophagy [38], and to cause differentiation [18] of glioma cells. The underlying molecular mechanisms include inhibition of mTOR by AMPK-dependent and independent ways and inhibition of Akt signaling [22, 38, 41]. In contrast to Static, metformin’s action on tumor cells is not limited to STAT3 inhibition. Multi-pathway inhibitory agents, such as metformin, may reduce the risk to induce resistance against therapy and may be more efficient than both specific inhibition of the EGFR/STAT3 and mTOR singaling pathways [42]. Effects of metformin on STAT3 have been described in non-malignant [43–53] and malignant tissues [23, 24, 54–64], with mainly inhibitory effects of metformin on STAT3-phosphorylation [23, 24, 43, 46–64]. However, one study also reported an increased level of STAT3 in the hypothalamus after metformin treatment [45] and two studies did not find a significant effect of metformin on STAT3 in brown adipocytes [44] and astroglial cells [65]. Only one prior study investigated STAT3 after metformin treatment in glioblastoma and observed a reduced phosphorylation at the Y705 binding site, but the results were merely based on two established glioma cell lines [24]. Our study

---

**Figure 7: Effects of the combination of Static and metformin on migration of BTICs and TCs.** A, B. Migration of BTIC-8 and -13 and C, D. TC-8 and -13 upon treatment with 1 mM metformin without or with the addition of 2.5, 5 and 10 μM Static, respectively. E. Migration of BTICs (summarized for BTIC-7, -8, -10, -11, 12, -13, -18) was not significantly more affected by the combination of metformin and Static than that of respective TCs (summarized for TC-7, -8, -10, -11, 12, -13, -18). Asterisks indicate significant differences as compared to the corresponding DMSO-control, the pound signs indicate significance as compared to 1 mM metformin.
confirmed those first findings in a number of primary
BTICs and TCs [23, 24, 54–64], which is closer to the in
vivo situation.

The exact mechanism, how metformin inhibits
phosphorylation of STAT3 has not been fully elucidated
yet. Although AMPK has been discussed as a mediator
between metformin and STAT3 signaling in prior studies
[59], other authors proposed also AMPK-independent
effects of metformin on STAT3 signaling [56]. In addition,
mTOR was shown to associate with STAT3 and to
facilitate STAT3 activation via specific mTOR-
dependent phosphorylation at Ser727 [66]. Knowing that
metformin inhibits activation of mTOR, this may be an
additional mechanism explaining the observed effects
and is supported by the fact, that the mTOR inhibitor
rapamycin also reduces STAT activation [66]. We did,
however, also observe reduced phosphorylation at Y705,
which may not be explained by the same, but possibly a
similar, yet undescribed, mechanism. For some BTICs
and TCs, metformin and Stattic treatment also reduced
levels of total STAT3 at high doses. Possibly, functional
inactivation of STAT3 by metformin or Stattic may also
lead to increased degradation of the total protein with
increasing doses.

STAT3 is known to mediate a metabolic switch
from oxidative phosphorylation to increased glycolysis
[67]. STAT3 inhibition by Stattic therefore reduces
STAT3-induced glycolysis and metformin inhibits
complex 1 of the respiratory chain. This might
represent an additional mechanism, explaining additive
effects. Additive effects of pharmacological partners
of metformin are highly desirable, as metformin was
mostly used in higher doses than usually reached in
diabetes treatment in most of the prior studies (among
others [17, 38]). The combination of metformin and
Stattic therefore allows a reduction of drug doses of the
single agents, thereby possibly reducing side effects by
maintaining inhibitory effects on tumor cells. However,
although metformin was administered at about 10% of
the dose used in other studies on glioma cells [17], drug
dosing still needs to be intensified in comparison to the
usual antidiabetic drug doses to reach concentrations of
1 mM in brain tissue [68].

To date, only a few specific STAT3 inhibitors, but
not Stattic, have been translated to clinical trials. For
instance, OPB-31121, which specifically inhibits STAT3-
phosphorylation was recently investigated in patients with
advanced solid tumors (but not brain tumors) in a phase I
trial [69] and showed the potential to stabilize (n = 8) or
reduce (n = 2) tumors (n = 18).

In summary, combining specific STAT3 inhibition
with the well tolerated and approved drug metformin may
represent a promising new strategy for the treatment of
high-grade glioma, but pharmacokinetic aspects, such as
drug delivery to the brain and clinically achievable drug
doses still need to be clarified.

MATERIALS AND METHODS

Ethics statement

The local department of neuropathology determined
the patients’ diagnoses and WHO grade, and routine
histopathology was accompanied by testing for IDH 1
mutation (by Sanger- or pyrosequencing) and MGMT
promoter methylation status (by MethyQESD [70]).
Clinical parameters such as age, gender, type of treatment,
and overall survival (according to the RANO criteria)
were available for all patients. The ethics committee of the
University of Regensburg, Regensburg, Germany (No° 11-
103-0182) approved the study and all patients gave written
informed consent.

Tumor cell lines

BTIC -7, -8, -10, -11, -12, -13, and -18 are primary
brain tumor cell cultures derived from resected human
glioblastoma as described before [19, 25]. For enrichment
of BTICs, tumor specimens were mechanically (and
partly also enzymatically) dissociated, washed with PBS
and passed through a cell strainer with 30-μm pore size
to obtain a single cell suspension (BD, #352235). Tumor
cells were maintained in RHB-A based serum-free culture
media (Takara, #Y40001), supplemented with 20 ng/ml of
the mitogens EGF (#130097751) and bFGF (#130093842)
(both Miltenyi Biotech), at 37 °C, 5% CO2, 95% humidity
in a standard tissue culture incubator. Progenitor features
of BTIC lines were verified by clonogenicity assays, and
partly by tumor take assays in an immunocompromised
mouse model. Differentiated TCs were generated via
exposure of BTICs to 10% FBS (Biochrom, #S0115)
in DMEM (#D6046) supplemented with 50 U (v/v)
Penicillin, 0.05% (v/v) Streptomycin (#P4333), 2 mM
(v/v) L-Glutamine (#G7513), 1% (v/v) MEM Vitamin
Solution (#M6895) and 1% (v/v) non-essential amino
acids (#M7145) (all Sigma-Aldrich) for at least 14 days.

Proliferation assay

As described before [71], proliferation was assessed
according to the manufacturers’ protocol by CyQUANT®
Direct Cell Proliferation Assay (Thermo Scientific,
#C35012). Briefly, cells were seeded considering
their stereotypic growing characteristics in different
amounts, i.e. at densities of 2.5, 3.75 and 5 × 10^4 cells/
ml, respectively, in 100 μl/well. Non-adherent cells were
seeded on laminin- (Corning, #354 232) coated wells
and incubated for 4 h. 72 h later the media was renewed
and cell triplicates treated with specific concentrations
of metformin, Stattic or a combination of both. 100 μl/
well CyQuant Direct Solution were applied 1 h prior to
measurement (excitation: 480 nm, emission: 535 nm).
Proliferation was measured at the start of the assay (0 h),

www.impactjournals.com/oncotarget
8258 Oncotarget
and at 48 and 96 h respectively. Blank values measured at every time point (100 μl media) and serial cell number dilutions served as references. For all assays, background fluorescence was subtracted and values were normalized to 0 h. Assays were performed in triplicates and repeated twice.

**Migration assay**

Tumor spheroids were generated by seeding 5 x 10^3 cells onto agarose-coated wells (1% agarose in 1x PBS) as described [19, 25, 71]. Cells were cultured for 48 h to allow spheroid formation. Mature spheroids were transferred into non-coated 96-well plates containing the corresponding drugs. Cell migration was monitored at 0, 16, 24, 40 and 48 h, taking into account the earliest time point when migration was measurable to prevent dilution of results by proliferation effects. The area covered by cells was measured manually (ImageJ software, NIH, USA) by an investigator. Assays were performed in triplicates and repeated twice.

**Organotypic brain slice cultures (OBSC)**

OBSC were prepared according to Gogolla et al. [72] with customized modifications. Briefly, rat pups (postnatal day 12) obtained from an in-house facility (Long-Ewans, Sprague Dawley or Wistar) were killed by cervical dislocation and used to obtain OBSCs, as described [19].

48 h prior to implantation, lentivirally transduced BTICs were seeded onto agarose coated 96-well plates (10,000 cells/well) to allow for spheroid formation. BTIC-13, BTIC-12 and BTIC-10 were lentivirally transduced using a U57 pHR SFFV GFP plasmid while BTIC-8 was transduced with pLenti-H1-(shRNA-Neg-control)-Rsv(RFP-Bsd). One spheroid per hemisphere was placed onto the lateral ventricle, facing the hippocampal formation. Cell culture medium, also when containing changes, was changed every other day.

In order to monitor spheroid migration, implanted spheroids were visualized at 5-fold magnification under a fluorescent microscope (Zeiss Axio Observer.Z1, Visitron Systems GmbH, #3834003816) once a week. Several pictures of one infiltration site were merged when necessary using Pixelmator software, version 3.3.2.

**Protein isolation and western blot**

To investigate protein levels of (p)STAT3, (p)mTOR, (p)AMPK, or GAPDH, whole-cell lysates were prepared with RIPA buffer (Perbio, #78440). For Western blot analysis, 30 μg of total cell lysates were diluted in Laemmli buffer, separated on a 10% SDS-PAGE gel and transferred to nitrocellulose membranes by semi-dry blotting. The membranes were blocked with 5% milk powder or 5% BSA in 0.02% Tween in TBS for 1 h. Membranes were incubated with specific monoclonal antibodies for STAT3 (#9145), pSTAT3 (phosphorylation site Y705, #9132 and S727, #9134), mTOR (#2983), pmTOR (phosphorylation site Ser2448, #5536), AMPK (#2603), pAMPK (phosphorylation site Thr172, #2535), all from Cell Signaling), or GAPDH (#sc-48167, Santa-Cruz) overnight at 4°C. Immunocomplexes were visualized using horseradish peroxidase-conjugated antibodies (goat anti-rabbit, Advansta #R-05072-500), donkey anti-goat (Santa-Cruz, #sc-2020)) followed by enhanced chemoluminescence (Western Bright Sirius ECL, Biozym #541-021). All Western blots were performed in duplicate. If several GAPDH controls are presented, the corresponding pairs are indicated by the same number of asterisks/pounds signs. Several GAPDH bands occurred, if we diluted not only 1x (30 μg) but 2x (60 μg) or more of the total cell lysates in Laemmli buffer and put the same sequence of cell lysates 2- times or more on the gel to reduce the number of stripping steps to evaluate several antibodies with similar molecular weight.

**RNA isolation and quantitative real time PCR (qRT-PCR)**

For RNA isolation, cells were incubated in 6-well plates (2 x10^3 cells per 2 ml). Total RNA was isolated by use of the Nucleo Spin RNA Plus Kit (Macherey-Nagel, #740 984.25) according to the manufacturer’s instructions. Reverse transcription was performed with the Reverse Transcription System (Promega, #A3500) according to the manufacturer’s protocol.

Quantification of STAT3 (forward: 5′-AAA GCA GCA AAG AAG GAG GC-3′, reverse: 5′-CTG GCC GAC AAT ACT TTC CG-3′) mRNA expression was performed by real-time PCR (Mx3000P Quantitative PCR [qPCR] System, Stratagene) based on SYBR-Green I fluorescence (Brilliant III Ultra Fast SYBR GREEN QPCR Master Mix, Agilent Technologies, #600883) using the ΔΔCT-method. RPLPO (large ribosomal protein) (forward: 5′-CTG TCT GCA GAT TGG CTA CCC-3′, reverse: 5′-GAT GGA TCA GCC AAG AAG GC-3′) served as housekeeping gene. Annealing temperatures were optimized for each primer pair. Three serial fivefold dilutions of cDNA, a mixture of all used cDNA-samples, were amplified in duplicates to construct standard curves for both the target gene and the reference (RPLPO, ribosomal protein, large, P0). cDNA-samples of BTICs were diluted 1:10. All samples were used in triplicates. For each reaction, melting curves were used to verify the identity of the amplification products. The target gene amount was divided by the reference (RPLPO) amount. Each of the experimental normalized values was divided by the normalized control (untreated) sample value to generate relative expression levels in fold changes.
Stable STAT3 overexpression

To achieve stable overexpression of STAT3, BTIC-8 and BTIC13 were lentivirally transduced with pLenti-Tet(CMV)-stat3C-Mut -Rsv(GFP-Puro). The plasmid was made according to the publication of Carro et al. [10] and purchased from AMS Biotechnology.

Statistics

Analyses of significant differences between treatment groups (mean values and SDs) were performed by two-way ANOVA. We used Dunnett’s test to control for multiple comparisons. The level of significance was set at *P<0.05, **P<0.01, ***<0.001 and ****P<0.0001. Data were analyzed using GraphPad Prism software (version 6, GraphPad Software, USA). In analyses comparing the combination of metformin and Stattic to the single agents, we used the asterisk to indicate significant differences as compared to the corresponding DMSO-control, whereas the pound sign indicates significance as compared to 1 mM metformin.

ACKNOWLEDGMENTS

We cordially thank Ina Weig-Meckl and Birgit Jachnik for excellent technical assistance. We thank Prof. Geley (Biocenter, Division of Molecular Pathophysiology, Innsbruck Medical University) for the kind gift of the U57 pHRSFFV GFP plasmid.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

This study was supported by the German Research Foundation (KFO262-P10, to C.S.).

REFERENCES


33. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000; 19:2548-56.


prevents hepatic insulin resistance induced by excess mTORC1/STAT3/Notch1 pathway by activated AMPK


Mahlapuu M. Partial hepatic resistance to IL-6-induced inflammation develops in type 2 diabetic mice, while the anti-inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes. Molecular and cellular endocrinology. 2013; 375:68-78.


Cansby E, Nerstedt A, Amrutkar M, Duran EN, Smith U, Mahlapuu M. Partial hepatic resistance to IL-6-induced inflammation develops in type 2 diabetic mice, while the anti-inflammatory effect of AMPK is maintained. Molecular and cellular endocrinology. 2014; 393:143-51.


